Moreover, neuropathies characterized by poor prognosis, including amyloid neuropathy, polyneuropathy, visceral hypertrophy, endocrine disorders, M-protein, and cutaneous changes (POEMS) syndrome, offer more quantifiable metrics for their treatment (e.g., survival rates). Here, MYOM2 is linked to neuropathy.